Shandong Buchang Pharmaceuticals Co., Ltd. (603858) Stock Analysis

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -5.47% and Operating profit at -44.63% over the last 5 years

With a growth in Net Profit of 4.29%, the company declared Very Positive results in Mar 25

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 20,152 Million (Large Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.16

Return on Equity

-2.77%

Price to Book

1.88

Revenue and Profits:

Net Sales:

2,839 Million

(Quarterly Results - Jun 2025)

Net Profit:

300 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-11.33%

6 Months

0.54%

1 Year

-0.59%

2 Years

-5.16%

3 Years

-30.7%

4 Years

-9.57%

5 Years

-32.39%

Shandong Buchang Pharmaceuticals Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Shandong Buchang Pharmaceuticals Reports Strong Quarterly Profits Amidst Market Challenges

Shandong Buchang Pharmaceuticals Co., Ltd., a prominent player in the pharmaceuticals and biotechnology sector, has recently released its financial results for the quarter ending March 2025. Despite facing a challenging market environment, the company has demonstrated resilience with notable performance metrics.

In the latest quarter, Shandong Buchang Pharmaceuticals achieved an operating profit of CNY 377.47 MM, marking a significant milestone for the company. This figure represents the highest operating profit recorded in recent times, showcasing the company's ability to maintain profitability even in adverse conditions.

Additionally, the pre-tax profit reached CNY 373.97 MM, further underscoring the company's robust financial health. The net profit for the quarter also hit a record high of CNY 305.66 MM, reflecting effective cost management and operati...

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-5.47%

EBIT Growth (5y)

-44.63%

EBIT to Interest (avg)

9.21

Debt to EBITDA (avg)

1.59

Net Debt to Equity (avg)

0.18

Sales to Capital Employed (avg)

0.82

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

8.76%

ROE (avg)

7.29%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.88

EV to EBIT

181.19

EV to EBITDA

30.70

EV to Capital Employed

1.76

EV to Sales

1.97

PEG Ratio

Dividend Yield

ROCE (Latest)

0.97%

ROE (Latest)

-2.77%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 3.62% vs 11.61% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 3.59% vs 131.50% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,839.40",
          "val2": "2,740.20",
          "chgp": "3.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "531.70",
          "val2": "519.40",
          "chgp": "2.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "31.10",
          "val2": "28.70",
          "chgp": "8.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.30",
          "val2": "2.10",
          "chgp": "-38.10%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "300.30",
          "val2": "289.90",
          "chgp": "3.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "137.30%",
          "val2": "137.80%",
          "chgp": "-0.05%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -16.75% vs -11.48% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -562.41% vs 109.55% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,846.80",
          "val2": "13,029.80",
          "chgp": "-16.75%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,297.20",
          "val2": "1,650.20",
          "chgp": "-21.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "135.70",
          "val2": "112.60",
          "chgp": "20.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-898.60",
          "val2": "-658.50",
          "chgp": "-36.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-702.40",
          "val2": "151.90",
          "chgp": "-562.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "63.10%",
          "val2": "80.60%",
          "chgp": "-1.75%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

2,839.40

2,740.20

3.62%

Operating Profit (PBDIT) excl Other Income

531.70

519.40

2.37%

Interest

31.10

28.70

8.36%

Exceptional Items

1.30

2.10

-38.10%

Consolidate Net Profit

300.30

289.90

3.59%

Operating Profit Margin (Excl OI)

137.30%

137.80%

-0.05%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 3.62% vs 11.61% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 3.59% vs 131.50% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

10,846.80

13,029.80

-16.75%

Operating Profit (PBDIT) excl Other Income

1,297.20

1,650.20

-21.39%

Interest

135.70

112.60

20.52%

Exceptional Items

-898.60

-658.50

-36.46%

Consolidate Net Profit

-702.40

151.90

-562.41%

Operating Profit Margin (Excl OI)

63.10%

80.60%

-1.75%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -16.75% vs -11.48% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -562.41% vs 109.55% in Dec 2023

All Annual Results

Company CV

About Shandong Buchang Pharmaceuticals Co., Ltd.

Shandong Buchang Pharmaceuticals Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Shandong Buchang Pharmaceuticals Co., Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of -5.47% and Operating profit at -44.63% over the last 5 years

With a growth in Net Profit of 4.29%, the company declared Very Positive results in Mar 25

Risky -

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Shandong Buchang Pharmaceuticals Reports Strong Quarterly Profits Amidst Market Challenges

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Shandong Buchang Pharmaceuticals Co., Ltd.

Company Coordinates